No analysis demonstrated a statistical difference between celecoxib and any comparator (Table 6).
35 Eight studies used a comparator intervention (table 2).
The studies varied in terms of sample size, length of follow-up and the presence of a comparator (see Table 1).
There was no difference in serious adverse event rates for celecoxib compared with paracetamol, rofecoxib, NSAID (Fig. 2), or any active comparator (Table 4).
The numbers of patients with a CV event per 1000 patient-years of follow-up are lower with all saxagliptin regimens combined than with all comparators (Table 2).
Discontinuations from the clinical trials as a result of an AE or SAE were also infrequent with saxagliptin and similar to placebo or comparator (Table 2).
In clinical trials, saxagliptin was generally well tolerated, with the incidence of AEs and SAEs similar to placebo or comparator (Table 2).
To this end, the lower log(SFRP4) tertile was set as reference category (HR 1.0) and the upper tertile as the comparator (Table 6).> -wrap-foot>> -wrap-foot>> -wrap-foot>> -wrap-foot>> -wrap-foot> > -wrap-foot> Categorical variables are shown as rate (number).
In the between group analyses, only the Weight Watchers arm achieved a statistically significantly greater weight loss and percentage weight loss than the exercise only comparator (tables 3 and 4).
In the between group analyses, only the commercial providers (Weight Watchers and Rosemary Conley) had a statistically significantly greater weight loss and percentage weight loss than the exercise only comparator (tables 3 and 4).
